News

Improvement in the diagnosis of testosterone deficiency syndrome in men allows an early treatment

The testosterone deficiency syndrome (TDS) is a clinical and biochemical syndrome associated with advancing age. It Is produced by a gradual drop in testosterone levels which affects the sexual sphere, leading to a decrease in sexual desire and morning erections, as well as decreasing the quality and frequency of erections. It can also affect the […]

Leer más about Improvement in the diagnosis of testosterone deficiency syndrome in men allows an early treatment

IDIBELL’s researcher Eva González-Suárez awarded with a grant from Susan G. Komen® to investigate new therapies in breast cancer

The research group leader in transformation and metastasis of the Bellvitge Biomedical Research Institute (IDIBELL), Eva González-Suárez, has been awarded with a research grant from Susan G. Komen®, the world’s leading breast cancer organization. The project is funded with 450 000 dollars for the next three years. Komen was founded in 1982 with the goal […]

Leer más about IDIBELL’s researcher Eva González-Suárez awarded with a grant from Susan G. Komen® to investigate new therapies in breast cancer

The epigenome differentiates the different human populations

What makes us different? What differentiates us from our neighbors, our friends or strangers from distant countries? For years we know that there are genetic differences among different human populations that contribute to their appearance and to a different susceptibility to disease. These small genetic differences between healthy individuals are called “polymorphisms”. The group of […]

Leer más about The epigenome differentiates the different human populations

Annual Report 2012

In 2012 the IDIBELL has positioned itself as a reference in healthcare innovation having driven a system of innovative public procurement in the field of health, in which the contractor and the bidder share the risks of the application of a new technology. The model, common in other countries, leverages the high purchasing capacity of […]

Leer más about Annual Report 2012

Patented a molecule that opens the door to develop new drugs against immune rejection

Researchers of the research group in Human Molecular Genetics of the Biomedical Research Institute of Bellvitge (IDIBELL), led by researcher Mercedes Pérez, have patented a peptide (a molecule consisting of a sequence of amino acids) that inhibits the immune response activated by the enzyme calcineurin which could serve to develop new more specific immunosuppressive drugs […]

Leer más about Patented a molecule that opens the door to develop new drugs against immune rejection

Learning a language depends on good connection between regions of the left hemisphere of the brain

Language is a uniquely human ability. The average person’s vocabulary consists of about thirty thousand words, although there are individual differences in the ability to learn a new language. It has long been believed that language acquisition depends on the integration of the information between motor and auditory representation of words in the brain, but […]

Leer más about Learning a language depends on good connection between regions of the left hemisphere of the brain

Discovered a future therapeutic target for lung cancer treatment

One of the goals of research in cancer genetics and molecular biology is to get an “on demand” treatment, ie studying the alterations in a tumor can decide which the best drug is: maximum effect and minimal toxicity. Two recent examples in this field are the findings that lung cancer patients carrying mutations in EGFR […]

Leer más about Discovered a future therapeutic target for lung cancer treatment

Dual effect of an antibiotic opens the door to find a drug against a very aggressive childhood cancer

An antibiotic that is currently used in veterinary named thiostrepton inhibits two transcription factors related to the appearance of Ewing’s sarcoma, a cancer that affects children and young people. It is a proof of concept done in cell lines and in mice. Although it is expected that the same molecule cannot be used directly in […]

Leer más about Dual effect of an antibiotic opens the door to find a drug against a very aggressive childhood cancer

The human papilloma virus multiplies the risk of oral cancer

HPV 16, one of the more aggressive types of HPV is present in over 30% of patients with cancers of the oropharynx and in less than 1% of healthy people HPV antibodies in blood HPV, responsible for more than 5% of cancers Early detection for better prognosis

Leer más about The human papilloma virus multiplies the risk of oral cancer
Scroll to Top